logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Musculoskeletal

Results

Drugs

November 2019

Palovarotene for flare-ups in fibrodysplasia ossificans progressiva – first line

Palovarotene is in clinical development for episodic use in the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP). FOP is a disabling condition, caused by the formation of bony bars within the muscles of the body (HO). This bone formation is usually first noticed in early childhood as a series of hard lumps in the neck or along the spine. These lumps, which may be tender, gradually shrink in size as the affected muscles are replaced by bone. The appearance of bony lumps in muscles is usually spontaneous but can also be provoked by any injury to the muscles.

Drugs

November 2019

Palovarotene for episodic and chronic use in fibrodysplasia ossificans progressiva – first line

Palovarotene is in clinical development for episodic and chronic use in the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP). FOP is a disabling condition, caused by the formation of bony bars within the muscles of the body (HO). This bone formation is usually first noticed in early childhood as a series of hard lumps in the neck or along the spine. These lumps, which may be tender, gradually shrink in size as the affected muscles are replaced by bone. The appearance of bony lumps in muscles is usually spontaneous but can also be provoked by any injury to the muscles.

Drugs

October 2017

Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis – after DMARD failure

There is currently no cure for rheumatoid arthritis. The most common treatment options are steroids to reduce inflammation, medications to reduce pain and inflammation and medications that slow the progression of joint damage from RA. Tocilizumab is already licensed for the treatment of RA as both intravenous and subcutaneous (pre-filled syringe) formulations, however its use, …

Drugs

May 2017

Tendoncel for the treatment of tennis elbow

Tendoncel is a gel which can be applied directly onto the skin of the elbow. Tendoncel gel contains a mixture of growth factors (a small substance which encourages cells to grow) which help the tendon to repair and heal. A clinical trial of tendoncel in people with severe tennis elbow showed improvements in elbow pain.If …

Drugs

May 2017

Romosozumab for osteoporosis in men

Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby increasing bone strength. The effectiveness and safety of romosozumab for the treatment of …

Drugs

April 2017

Romosozumab for postmenopausal osteoporosis

Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby increasing bone strength. The effectiveness and safety of romosozumab in women with postmenopausal …

Drugs

January 2017

Ixekizumab (Taltz) for psoriatic arthritis – second line

Psoriatic arthritis occurs when patients with skin psoriasis (a skin condition that causes itchy red, flaky, scaly patches of skin) also have joint involvement. People with psoriatic arthritis often feel pain and experience stiffness in their joints, for example, in the hands, feet, knees, neck, spine, and elbows.Ixekizumab is a new drug to treat psoriatic …

Drugs

January 2017

Belimumab (Benlysta) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis

Belimumab is a new drug to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (inflammation of the blood vessels). ANCA-associated vasculitis is a type of autoimmune inflammation caused by abnormal antibodies that attack the body’s own cells. Belimumab is given straight into the bloodstream and studies have suggested that it may help to treat ANCA-associated vasculitis by …

Drugs

January 2017

AXS-02 for the treatment of knee pain due to osteoarthritis

AXS-02 is a new drug to treat knee pain caused by osteoarthritis involving bone marrow lesions. Bone marrow lesions are associated with pain in patients with osteoarthritis. AXS-02 is taken once a day by mouth.

Drugs

January 2017

Avacopan for ANCA-associated vasculitis – first and subsequent line

Avacopan is a new drug to treat anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (inflammation of the blood vessels). ANCA-associated vasculitis is a type of autoimmune inflammation caused by abnormal antibodies that attack the body’s own cells. Avacopan is taken by mouth and some studies have suggested that it may help to treat ANCA-associated vasculitis by reducing …

Get Alerts